scPharmaceuticals Inc. 8-K Report: Key Developments on January 10, 2025
Based on the provided XML section from the financial report, here are the key details and insights extracted:
- Entity Information:
- Company Name: scPharmaceuticals Inc.
- CIK Number: 0001604950
- State of Incorporation: Delaware (DE)
- SEC File Number: 001-38293
- EIN: 46-5184075
- Address: 25 Mall Road, Suite 203, Burlington, MA 01803
- Contact Number: (617) 517-0730
- Filing Information:
- Form Type: 8-K (a report of unscheduled material events or corporate changes)
- Filing Date: January 10, 2025
- The document is part of a structured financial report format (XBRL).
- Stock Information:
- Common Stock Par Value: $0.0001 per share
- Ticker Symbol: SCPH
- Exchange: NASDAQ
- Period of Reporting:
- Start Date: January 10, 2025
- End Date: January 10, 2025
- The reporting period is for a single day, suggesting that this 8-K filing may contain specific, time-sensitive information pertinent to events occurring on that date.
Insights:
- The use of an 8-K form indicates that there may be significant information to disclose about the company, such as acquisitions, changes to the board, or other critical events.
- The par value of the common stock suggests that the company is in the early stages of its financial structure, which is common for biotech firms.
- Being listed on NASDAQ indicates that scPharmaceuticals Inc. is a publicly traded company, potentially subjecting it to greater scrutiny and regulatory requirements.
- The specific timeframe of the report suggests that it may respond to a particular event occurring on January 10, 2025, which investors and analysts should monitor closely for additional context and implications on the company’s future performance.
Further analysis would require access to the full 8-K filing to understand the specific events or developments reported.